Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Provention Bio, Inc. (PRVB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.49-0.22 (-3.28%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.71
Open6.50
Bid6.50 x 800
Ask6.53 x 1000
Day's Range6.42 - 6.77
52 Week Range5.59 - 20.05
Volume582,688
Avg. Volume540,034
Market Cap411.302M
Beta (5Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.79
  • Zacks

    Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know

    The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • PR Newswire

    Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway

    Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on its ongoing efforts to address U.S. Food and Drug Administration (FDA) considerations cited in the Complete Response Letter (CRL) issued to the Company by the FDA on July 2, 2021, pertaining to comparability between the Company's planned teplizumab commercial product and clinical drug product used in historical trials of teplizumab.

  • PR Newswire

    Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

    Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development. Dr. Hillson bolsters the Company's clinical development leadership group with significant experience in all phases of clinical development across various autoimmune disorders, including systemic lupus erythematosus, which is the lead target indication for PRV-3279,

Advertisement
Advertisement